Published in final edited form as:

Bioorg Med Chem. 2009 October 15; 17(20): 7126–7130. doi:10.1016/j.bmc.2009.08.061.

Natural Product Leads for Drug Discovery: Isolation, Synthesis and Biological Evaluation of 6-Cyano-5-methoxyindolo[2,3-*a*]carbazole Based Ligands as Antibacterial Agents

Songpo Guo^{a,b}, Suresh K. Tipparaju^{a,b}, Scott D. Pegan^c, Baojie Wan^d, Shunyan Mo^{b,c}, Jimmy Orjala^{b,c}, Andrew D. Mesecar^{b,c,d}, Scott G. Franzblau^d, and Alan P. Kozikowski^{b,*}

^bDrug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 833 S. Wood Street, Chicago, USA.

^cCenter for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 S. Ashland Avenue, Chicago, USA.

^dInstitute for Tuberculosis, Research College of Pharmacy, University of Illinois at Chicago, 833 S. Wood Street, Chicago, USA.

Abstract

Indolo[2,3-*a*]carbazole based inhibitors were synthesized from readily available indigo *via* a seven-step linear synthetic sequence with a moderate overall yield. The inhibitors were selectively and readily functionalized at the nitrogen on the indole portion of the carbazole unit. The synthesized analogs displayed moderate inhibitory activities toward *B. anthracis* and *M. tuberculosis*, indicating that indolo[2,3-*a*]carbazoles could serve as promising leads in the development of new drugs to combat anthrax and tuberculosis infections.

1. Introduction

The heterocyclic indolo[2,3-*a*]carbazole system is found in several biologically active natural products which are available from a variety of organisms. Examples of such natural products include the protein kinase inhibitor staurosporine (STS) from the bacterium *Streptomyces staurosporeus*,¹ anti-cancer agents such as the arcyliaflavins isolated from the slime mold *Arcyria denudate*,² and the topoisomerase I inhibitor rebeccamycin, which originates from the bacterium *Nocardia aerocoligenes* (Fig. 1).³ Due to the wide spectrum of biological activities exhibited by the naturally occurring carbazoles, a variety of synthetic analogs based on the indolo[2,3-*a*]carbazole scaffold have garnered considerable attention in the development of medicines for psoriasis, hypertension, cancer, and HIV-infection.⁴ During a screening effort for antibacterial agents from cyanobacteria, we identified a strong inhibitory activity towards *Bacillus anthracis* (*B. anthracis*) for the extract of *Nostoc muscorum* (UTEX 2301). Bioassay guided fractionation led to the isolation and identification of 6-cyano-5-methoxyindolo[2,3-*a*]carbazole (**1a**; Fig. 2) as the active principle.⁵ Compound **1a** and 6-cyano-5-methoxy-12-

© 2009 Elsevier Science. All rights reserved

kozikowa@uic.edu; Fax: +1312 996 7107; Tel: +1 312 996 7577(A. P. K).

^aThese authors contributed equally to this work

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

methyloindolo[2,3-*a*]carbazole (**1b**) were first isolated from the blue-green alga *Nostoc sphaericum* (strain EX-5-1) and identified by Moore and co-workers in 1990.⁵ In their studies, compound **1b** showed modest antiviral activity against herpes simplex virus type 2; in infected mink lung cells, the virus titer is reduced 95% at 1 $\mu\text{g/mL}$, and weak, non-selective cytotoxicity (MIC 5 $\mu\text{g/mL}$) against KB and LoVo human carcinoma cell lines.⁵

As part of an ongoing, multi-faceted program aimed toward developing novel anti-infective chemotherapeutics against potential bio-warfare agents⁶ and neglected diseases⁷, we synthesized and screened a set of compounds containing the indolo[2,3-*a*]carbazole system as a primary scaffold against *B. anthracis* and *Mycobacterium tuberculosis* (*M. tuberculosis*). Herein we report the synthesis and biological activity of some of these new indolo[2,3-*a*]carbazoles.

We noted that the chemical scaffold of antiviral indolo[2,3-*a*]carbazoles **1a** and **1b** was similar to the aglycone portion of the protein kinase inhibitor STS (Fig. 2). It is well known that the substituents on the indole nitrogens play a significant role in determining the biological activity of the indolocarbazoles. Varying these substituents with various uncommon sugars via an α - or β -*N*-glycosidic linkage was a key element for modulating their cytotoxicity, anticancer activity, and topoisomerase inhibition.⁸ For instance, rebeccamycin and its analogues with different sugar moieties were much more active than the corresponding aglycone.⁹

2. Chemistry

In view of the foregoing facts, we wished to evaluate the antibiotic activities of indolo[2,3-*a*]carbazoles (**1a–c**, **6a–c**, **7a**, **8** and **9**) with varying R^1 and R^2 substituents.

The advances in indolocarbazole chemistry were previously summarized in a comprehensive review focusing on carbazole and indolocarbazole synthesis.¹⁰ A survey of available literature on the synthesis of indolocarbazoles indicated that these inhibitors are generally synthesized through strategies involving either direct formation of the indolocarbazole skeleton by indole ring synthesis, elaboration of bisindole precursors by the construction of the central carbocyclic ring, or through a combination of these two strategies.¹¹ The first synthesis of **1a** and **1b** was reported by Somei et al. in 1997^{12c} and in the following years, they made extensive efforts toward optimizing those protocols.^{12a,b} In addition, Snieckus and co-workers reported an efficient route to indolo[2,3-*a*]carbazole **1b** via a metalation-cross-coupling reaction sequence.¹³ This protocol provided a useful way to modify the substituents on the indole portions of the carbazole scaffold. However, this method relied heavily on a very substrate-selective, Suzuki-Miyaura and Stille cross-coupling reactions of the two indole units that require elaborate synthesis themselves.

In our own efforts, we found that the syntheses described earlier were not readily amenable to modifications that enabled an easy build-up of a library of *N*-functionalized indolocarbazoles. For example, our attempts to modify Somei's synthesis by introducing a *tert*-butoxycarbonyl group as R^1 at the stage of intermediate **5a** failed (Scheme 1).

Alternatively, we were successful in functionalizing intermediate **5a** with an easily-cleavable benzyl group as R^1 and then selectively modifying R^2 . The synthesis started from 3-acetoxy-2,2'-bi-1*H*-indole¹⁴ (**3**), readily made from indigo (**2**). Intermediate **3** was reacted with dichloroacetyl chloride in refluxing anhydrous ethyl acetate to afford the 3-acetoxy-3'-dichloroacetyl-2,2'-biindolyl intermediate **4**.^{12d,e} Subsequent cyclization of **4** using aqueous ammonia in MeOH/DMF at ambient temperature provided the tetrahydroindolo[2,3-*a*]carbazole **5a**.^{12c} Methylation of **5a** with dimethyl sulfate in the presence of K_2CO_3 as a base resulted in the 12-methyl intermediate **5b** in quantitative yield, while benzylation of **5a** afforded **5c** under similar conditions in 83% yield. Reductive cyanation^{12c} of **5a** using only 5 equivalents

of NaCN instead of the 30 equivalents reported in the literature^{12c} gave **6a** in 34% yield in comparison to the reported yield of 60%. However, using the lower amounts of NaCN, the reductive cyanation of **5b** and **5c** took place in higher yields of 60% and 90%, respectively. Subsequent methylation of intermediates **6a–c** with diazomethane provided **1a–c** in excellent yields. The free indole nitrogen as well as the phenolic hydroxyl group of intermediates **6b** and **6c** were methylated to give the corresponding compounds **7a** and **7b**. Compound **7b** was subsequently treated with AlCl₃ in anisole at 110 °C to remove the *N*-benzyl group to form **8** in quantitative yield.¹⁵ The nitrile group at the 6-position of the indolo[2,3-*a*]carbazole **1b** was readily hydrolyzed in the presence of hydrogen peroxide to give the new carboxamide **9**.

3. Biological Studies

The synthesized derivatives were tested for their inhibitory activity against the Δ ANR strain of *B. anthracis* and H₃₇Rv strain of *M. tuberculosis*.¹⁶ The results are summarized in Table 1. While there was no clear effect on the activity of indolocarbazoles stemming from the presence or absence of an alkyl group R¹ (for example, compare **1a** vs **1b** against **6a** vs **6c** or **7a** vs **8**), compounds with R³ = H clearly displayed an improvement in their inhibitory activities (compare **1b** vs **6b** and **1a** vs **6a**). Significantly, it was interesting to note that the presence of an alkyl group as R² was detrimental to the activity of these indolocarbazoles (compare **1a** vs **8**). Replacement of the cyano functionality in **1b** with a carboxamide (compound **9**) did not alter activity for growth inhibition of *M. tuberculosis*. Interestingly, the protein kinase inhibitor STS displayed modest activity against *M. tuberculosis*, while it was inactive against *B. anthracis*. The newly synthesized analogs **6a–c** clearly had improved activities against both the pathogens compared to the known indolocarbazole **1b**. Benzyl protected compound **6c** was equipotent to **6a** in the inhibition of *B. anthracis*, while only 4-fold less potent than **6a** in the inhibition of *M. tuberculosis*. Similarly, **1c** with a benzyl protected indole moiety displayed a moderate MIC (44.1 μ M) against *M. tuberculosis*. Encouraged by these preliminary results, we are currently screening more *N*-functionalized indolo[2,3-*a*]carbazole derivatives to improve the activity of these promising leads.

4. Conclusions

In conclusion, a variety of indolo[2,3-*a*]carbazoles were synthesized from the commercially available and widely used indigo dye in seven linear steps. The described synthetic strategy allows selective functionalization of either of the indole nitrogens and is amenable to ready generation of a library of *N*-functionalized indolo[2,3-*a*]carbazole derivatives. Some of the synthesized compounds displayed reasonable activity against *B. anthracis* (compounds **1a**, **6a** and **6c**) and moderate activity against *M. tuberculosis* (compound **6a**). Further rounds of screening and optimization of these new indolo[2,3-*a*]carbazoles are currently in progress.

5. Experimental

5.1. Biology methods

5.1.1 Isolation of 1a from *Nostoc muscorum*—*Nostoc muscorum* was acquired from the Culture Collection of Algae at the University of Texas at Austin (UTEX 2301). The cyanobacterium was grown in a 2.8 L Fernbach flask containing 1 L of inorganic media (Allen). Cultures were illuminated with fluorescent lamps at 1.93 klx with an 18/6 hour light/dark cycle at 22 °C. After 6–8 weeks, the biomass of cyanobacteria was harvested by centrifugation and then freeze-dried. The freeze-dried biomass from a total of 7 L of culture (2.09 g) was extracted by repeated maceration with CH₂Cl₂: MeOH (1:1) to yield 246.8 mg of crude extract. The crude extract showed inhibitory activity towards *B. anthracis* (MIC 7.5 μ g/mL) and was fractionated on silica gel using a gradient with increasing amount of MeOH in CH₂Cl₂ to afford 16 fractions. Fraction 5 (MIC 0.94 μ g/mL) eluting with CH₂Cl₂:MeOH 60:1, was subjected to

reversed-phase HPLC (Alltima C₁₈, 10 μ m, 250 $\times$ 10 mm, 4 mL/min) with a solvent gradient of acetonitrile–H₂O (10:90) to acetonitrile–H₂O (90:10) over 35 min to afford one major compound (t_R = 29.8 min, 13.3 mg). The structure was identified by spectroscopic means (1D, 2D, NMR and MS) and the data were found to be identical to those previously reported for 6-cyano-5-methoxy-indolo[2,3-*a*]carbazole.

5.1.2 MIC against the Δ ANR strain of *B. anthracis*—The test compound MIC values against the Δ ANR (plasmid-cured Ames Strain) of *B. anthracis* were determined using an automated Microplate-based Alamar Blue assay. Assays were carried out using a TECAN Freedom Evo 200 liquid-handling robotics platform equipped with a TeMO96 multichannel pipette and TECAN GENios Pro spectrophotometer. Using the TeMO96, 50 μ L of Cation-Adjusted Mueller-Hinton Broth (CAHB) was added to each well of a sterile, Falcon MICROTTEST 96-well flat bottom tissue culture plate. A serial dilution of the desired inhibitors was created by adding 46 μ L of the CAHB, using the Freedom Evo 200's 8 channel liquid handling arm (LiHa), to each well of the first column which also contained 4 μ L of inhibitor at 10 mM. Upon mixing, 50 μ L of the first wells was transferred to the next column and mixed. This routine was repeated ten more times to generate the desired gradient. Sample and positive control wells were inoculated using the TeMo96 with 50 μ L of a diluted *B. anthracis* Δ ANR bacterial culture, whereas 50 μ L of CAHB containing no bacteria was added to the negative control wells. Stock bacterial cultures were grown to mid-log phase (OD₆₀₀ = 0.4–0.6), and diluted to the desired OD₆₀₀ of 0.004 using fresh CAHB. After the final inoculation with the bacterial culture, the microplates were incubated at 37 °C overnight (~14 h) without agitation. After incubation, 5 μ L of alamar blue dye (Serotec) was added to each well using the TeMo96. Plates were agitated for 15 min at 900 rpm on a TECAN TeShake, and the absorbance values at wavelengths of 570 nm and 600 nm were then measured using the TECAN GENios Pro. Individual wells were quantitatively assessed using the difference between the absorbance values at 600 nm and 570 nm. MICs for each compound and known antibiotic were assigned based on the first well that exhibited a negative absorbance difference, representative of no bacterial growth.

5.1.3 MIC against H₃₇Rv strain of *M. tuberculosis*—The compound MICs against replicating *M. tuberculosis* were assessed by the Microplate Alamar Blue assay¹⁶ (MABA) using rifampin and isoniazid as positive controls. Compound stock solutions were prepared in DMSO at a concentration of 12.8 mM, and the final test concentrations ranged from 128 μ M to 0.5 μ M. Two fold dilutions of compounds were prepared in Middlebrook 7H12 medium (7H9 broth containing 0.1% w/v casitone, 5.6 μ g/mL palmitic acid, 5 mg/mL bovine serum albumin, 4 mg/mL catalase, filter-sterilized) in a volume of 100 μ L in 96-well microplates (black viewplates, manufacturer). *M. tuberculosis* H₃₇Rv (ATCC#27294) (100 μ L inoculum of 1 $\times$ 10⁵ cfu/mL) was added, yielding a final testing volume of 200 μ L. The plates were incubated aerobically at 37 °C. On the 7 day of incubation 12.5 μ L of 20% Tween 80, and 20 μ L of Alamar Blue (Trek Diagnostic, Westlake, Ohio) were added to the test plate. After incubation at 37 °C for 16–24 h, fluorescence of the wells was measured (ex 530, em 590 nm). The MICs were defined as the lowest concentration effecting a reduction in fluorescence of $\geq$ 90% relative to the mean of replicate bacteria-only controls.

5.2. Chemistry methods

¹H NMR and ¹³C NMR spectra were recorded on Bruker spectrometer with TMS as an internal standard. Standard abbreviation indicating multiplicity was used as follows: s = singlet, d = doublet, t = triplet, q = quadruplet, quin = quintuplet, m = multiplet and br = broad. HRMS experiment was performed on Q–TOF–2TM (Micromass). The progress of all reactions was monitored by TLC on precoated silica gel plates (Merck Silica Gel 60 F254). Column chromatography was performed using Merck silica gel (230–400 mesh). All reactions were

performed under inert atmosphere of nitrogen, unless otherwise mentioned. All spectral data of known compounds are identical to those reported.^{5, 12}

5.2.1. *Cis*-6-chloro-6a-hydroxy-5-oxo-12-benzyl-5,6,6s,12-tetra- hydroindolo

[2,3-*a*]carbazole 5c from 5a—K₂CO₃ (2500 mg, 18.1 mmol) and benzyl bromide (5500 mg, 32.2 mmol) were added to a solution of **5a** (1000 mg, 3.23 mmol) in DMF (30 mL), and the mixture was stirred at room temperature for 2 hours. After addition of the H₂O under ice water bath, the whole solution was extracted with EtOAc. The extract was washed by brine, dried over Na₂SO₄, and evaporated under reduced pressure to leave a residue, which was column-chromatographed on SiO₂ with EtOAc–Hexane (1:2, v/v) to give **5c** (1.1 g, 83%). ¹H NMR (DMSO-*d*₆, 400 MHz) δ (ppm): 8.20 (d, *J* = 7.6 Hz, 1H), 7.87 (d, *J* = 7.6 Hz, 1H), 7.77 (d, *J* = 7.6 Hz, 1H), 7.66 (d, *J* = 8.0 Hz, 1H), 7.54 (t, *J* = 7.6 Hz, 1H), 7.50–7.35 (m, 5H), 7.35–7.15 (m, 3H), 6.96 (s, 1H), 6.19 (d, *J* = 15.6 Hz, 1H), 6.00 (d, *J* = 15.6 Hz, 1H), 5.45 (s, 1H); ¹³C NMR (DMSO-*d*₆, 100 MHz) δ (ppm): 185.1, 169.4, 154.9, 139.2, 138.9, 136.7, 136.5, 130.6, 128.8, 127.8, 127.4, 126.9, 126.3, 125.4, 124.3, 123.8, 122.2, 121.6, 115.5, 112.3, 87.5, 69.8, 47.8; HRMS (ESI) calculated for C₂₅H₁₇ClN₂O₂ [M+H]⁺ 413.1051, found 413.1073.

5.2.2. 6-Cyano-5-hydroxy-12-benzylindolo[2,3-*a*]carbazole (6c) from 5c

—NaCN (654 mg, 13.4 mmol) was added to a solution of **5c** (1100 mg, 2.7 mmol) in DMF (40 mL) and H₂O (20 mL), and the solution was stirred at 70 °C for 30 min. After addition of H₂O, the whole solution was extracted by EtOAc. The extract was washed by brine, dried over Na₂SO₄, and evaporated under reduced pressure to leave a residue, which was column-chromatographed on SiO₂ with EtOAc–Hexane (1:2, v/v) to give **6c** (947 mg, 90%). ¹H NMR (DMSO-*d*₆, 400 MHz) δ (ppm): 11.74 (s, 1H), 10.83 (s, 1H), 8.48 (d, *J* = 7.6 Hz, 1H), 8.41 (d, *J* = 8.0 Hz, 1H), 7.75–7.60 (m, 2H), 7.55–7.38 (m, 2H), 7.38–7.05 (m, 7H), 6.14 (s, 2H); ¹³C NMR (DMSO-*d*₆, 100 MHz) δ (ppm): 152.5, 140.4, 139.5, 137.9, 130.7, 128.8, 127.5, 126.7, 125.8, 125.2, 122.8, 122.3, 121.1, 120.8, 119.7, 119.6, 119.5, 119.4, 118.5, 112.3, 111.4, 110.3, 82.2, 47.5; HRMS (ESI) calculated for C₂₆H₁₇N₃O [M+H]⁺ 388.1444, found 388.1461.

5.2.3. 6-Cyano-5-methoxy-11-methyl-12-methylindolo[2,3-*a*]carbazole (7a) from 6b

—K₂CO₃ (38 mg, 0.28 mmol) and MeI (197 mg, 1.4 mmol) were added to a solution of **6b** (43 mg, 0.14 mmol) in DMF (2 mL), and the mixture was stirred at rt for 2 h. After addition of the H₂O under ice water bath, the whole solution was extracted with EtOAc. The extract was washed by brine, dried over Na₂SO₄, and evaporated under reduced pressure to leave a residue, which was column-chromatographed on SiO₂ with EtOAc–Hexane (1:2, v/v) to give **7a** (41 mg, 90%). ¹H NMR (CDCl₃, 400 MHz) δ (ppm): 8.66 (d, *J* = 8.0 Hz, 1H), 8.31 (d, *J* = 7.6 Hz, 1H), 7.70–7.45 (m, 4H), 7.45–7.20 (m, 2H), 4.30 (s, 3H), 4.20 (s, 3H), 4.12 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm): 154.8, 143.9, 142.3, 132.4, 126.3, 125.7, 125.3, 122.5, 122.0, 121.9, 121.0, 120.8, 120.2, 117.3, 115.2, 110.0, 109.5, 87.5, 61.7, 36.5, 36.0; HRMS (ESI) calculated for C₂₂H₁₇N₃O [M+H]⁺ 340.1444, found 340.1457.

5.2.4. 6-Cyano-5-methoxy-11-methyl-12-benzylindolo[2,3-*a*]carbazole (7b) from 6c

—Synthesized by method above by using **6c** as a starting material. Yield = 95%. ¹H NMR (CDCl₃, 400 MHz) δ (ppm): 8.70 (d, *J* = 8.0 Hz, 1H), 8.38 (d, *J* = 7.2 Hz, 1H), 7.60–7.10 (m, 11H), 5.75 (s, 2H), 4.35 (s, 3H), 3.80 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm): 154.8, 144.0, 142.3, 136.5, 132.5, 128.9, 128.2, 127.3, 126.4, 125.8, 125.4, 122.7, 122.4, 122.3, 122.1, 121.5, 120.8, 120.2, 177.2, 115.8, 110.8, 110.0, 88.0, 61.8, 51.8, 36.2; HRMS (ESI) calculated for C₂₈H₂₁N₃O [M+H]⁺ 416.1757, found 416.1768.

5.2.5. 6-Cyano-5-methoxy-12-methylindolo[2,3-*a*]carbazole (8) from 7b

—To a stirred suspension of AlCl₃ (143 mg, 1.1 mmol) in anisole (5 mL) in an ice bath was added a solution of **7b** (80 mg, 0.2 mmol) in anisole (5 mL). The mixture was stirred at 110 °C for 2

hr. The reaction mixture was poured into water (20 mL) and extracted with EtOAc. The extracts were washed with 5% NaHCO₃ (10 mL), water (10 mL), and brine (10 mL) and dried over Na₂SO₄. The solvent was evaporated, and the residue column-chromatographed on SiO₂ with EtOAc–Hexane (1:2, v/v) to give **8** (62 mg, 100%). ¹H NMR (DMSO-*d*₆, 400 MHz) δ (ppm): 12.16 (s, 1H), 8.46 (d, *J* = 7.6 Hz, 1H), 8.24 (d, *J* = 8.0 Hz, 1H), 7.90–7.70 (m, 2H), 7.63–7.45 (m, 2H), 7.45–7.25 (m, 2H), 4.36 (s, 3H), 4.22 (s, 3H); ¹³C NMR (DMSO-*d*₆, 100 MHz) δ (ppm): 154.4, 140.8, 139.8, 129.2, 126.1, 125.8, 123.9, 121.7, 121.0, 120.9, 120.8, 119.7, 119.6, 117.8, 117.7, 113.8, 112.1, 110.2, 86.1, 62.2, 31.9; HRMS (ESI) calculated for C₂₁H₁₅N₃O [M+H]⁺ 326.1288, found 326.1302.

5.2.6. 5-methoxy-12-methylindolo[2,3-*a*]carbazole-6-carboxylic acid amide (**9**)—

A mixture of the nitrile **1b** (44 mg, 0.14 mmol), 35% hydrogen peroxide (0.1 mL) and 3N aqueous NaOH (0.03 mL) in ethanol (2 mL) was stirred at 30 °C for 20 h. The resulting mixture was acidified with 1N sulphuric acid, the precipitate was filtered, dried, which was column-chromatographed on SiO₂ with MeOH–CH₂Cl₂ (1:19, v/v) to afford the compound **9** (33 mg, 70%). ¹H NMR (Acetone-*d*₆, 400 MHz) δ (ppm): 11.10 (br s, 1H), 8.62 (d, *J* = 8.0 Hz, 1H), 8.35 (d, *J* = 7.8 Hz, 1H), 7.71 (t, *J* = 8.2 Hz, 2H), 7.57 (t, *J* = 7.2 Hz, 1H), 7.51 (t, *J* = 7.4 Hz, 1H), 7.37 (q, *J* = 7.8 Hz, 2H), 4.45 (s, 3H), 4.32 (s, 3H); ¹³C NMR (Acetone-*d*₆, 100 MHz) δ (ppm): 170.1, 154.6, 140.3, 140.2, 125.7, 125.3, 121.7, 121.4, 121.2, 120.3, 119.4, 116.9, 112.7, 111.5, 109.0, 86.5, 61.2, 41.7; HRMS (ESI) calculated for C₂₁H₁₇N₃O₂ [M+H]⁺ 344.1395, found 344.1399.

Acknowledgments

This work was supported in part by DOD (W81XWH-07-1-0445) and by NIH Grant (1R01GM075856).

References

- Omura S, Iwai Y, Hirano A, Nakagawa A, Awaya J, Tsuchiya H, Takahashi Y, Masuma R. J. Antibiotics 1977;30:275. [PubMed: 863788]
- Steglich W, Steffan B, Kopanski L, Eckhardt G. Angew. Chem., Int. Ed. Engl 1980;19:459.
- Bush JA, Long BH, Catino JJ, Bradner WT, Tomita K. J. Antibiotics 1987;40:668. [PubMed: 3112080]
- Sanchez C, Mendez C, Salas JA. Nat. Prod. Rep 2006;23:1007. [PubMed: 17119643]
- Knubel G, Larsen LK, Moore RE, Levine IA, Patterson GML. J. Antibiotics 1990;43:1236. [PubMed: 2175302]
- (a) Tipparaju SK, Mulhearn DC, Klein GM, Chen Y, Tapadar S, Bishop MH, Yang S, Chen J, Ghassemi M, Santarsiero BD, Cook JL, Johlfs M, Mesecar AD, Johnson ME, Kozikowski AP. Chem. Med. Chem 2008;3:1250. [PubMed: 18663709] (b) Tipparaju SK, Joyasawal S, Forrester S, Mulhearn DC, Pegan S, Johnson ME, Mesecar AD, Kozikowski AP. Bioorg. Med. Chem. Lett 2008;18:3565. [PubMed: 18499454]
- Tipparaju SK, Joyasawal S, Pieroni M, Kaiser M, Brun R, Kozikowski AP. J. Med. Chem 2008;51:7344. [PubMed: 18989953]
- Bailly C, Qu X, Anizon F, Prudhomme M, Riou J, Chaires JB. Mol. Pharm 1999;55:377.
- Zhang G, Shen J, Cheng H, Zhu L, Fang L, Luo S, Muller MT, Lee GE, Wei L, Du Y, Sun D, Wang PG. J. Med. Chem 2005;48:2600. [PubMed: 15801850]
- Knolker HJ, Reddy KR. Chem. Rev 2002;102:4303. [PubMed: 12428991]
- Janosik T, Wahlstrom N, Bergman J. Tetrahedron 2008;64:9159.
- (a) Somei M, Yamada F, Suzuki Y, Ohmoto S, Hayashi H. Heterocycles 2004;64:483. (b) Hayashi H, Suzuki Y, Somei M. Heterocycles 1999;51:1233. (c) Hayashi H, Ohmoto S, Somei M. Heterocycles 1997;45:1647. (d) Somei M, Hayashi H, Ohmoto S. Heterocycles 1997;44:169. (e) Somei M, Hayashi H, Izumi T, Ohmoto S. Heterocycles 1995;41:2161.
- Cai X, Snieckus V. Org. Lett 2004;6:2293. [PubMed: 15228262]

14. (a) Madelung W, Siegert P. Ber. Dtsch. Chem. Ges 1924;57:222. (b) Bergman J, Eklund N. *Chemica Scripta* 1982;19:193. (c) McGovern PE, Michel RH. *Acc. Chem. Res* 1990;23:152.
15. Wada Y, Nagasaki H, Tokuda M, Orito K. *J. Org. Chem* 2007;72:2008. [PubMed: 17309305]
16. Collins L, Franzblau SG. *Antimicrob. Agents Chemother* 1997;41:1004. [PubMed: 9145860]

Fig. 1.
Indolo[2,3-*a*]carbazole based natural products: arcyriaflavins A–D and rebeccamycin

Fig. 2.
An overlay of chemical structures of STS and indolo[2,3-*a*]carbazoles **1a** and **1b**

Scheme 1.

Synthesis of indolocarbazoles **1a–c**, **6a–c**, **7a**, **8** and **9**. *Reagents and conditions:* (a) Sn, AcOH, Ac₂O, 64–66 °C; (b) Cl₂CHCOCl, EtOAc, reflux; (c) aq. 1.3 % NH₃, MeOH, DMF, rt; (d) Me₂SO₄, K₂CO₃, DMF, rt; (e) BnBr, K₂CO₃, DMF, rt; (f) NaCN, DMF, H₂O, 70 °C; (g) CH₂N₂, rt; (h) MeI, K₂CO₃, DMF, rt; (i) AlCl₃, Anisole, 110 °C, 2 h; (j) 35% H₂O₂, 3 N NaOH, EtOH, 30 °C, 20 h.

Table 1

Inhibition of *B. anthracis* and *M. tuberculosis* by compounds **1a–c**, **6a–c**, **7a**, **8** and **9**.

Compound	R ¹	R ²	R ³	R ⁴	MIC ^a (<i>B. anthracis</i>) (μ M)	MIC ^b (<i>M. tuberculosis</i>) (μ M)
1a	H	H	Me	CN	6.3	> 128
1b	Me	H	Me	CN	> 200	> 128
1c	Bn	H	Me	CN	> 200	44.1
6a	H	H	H	CN	1.6	15.0
6b	Me	H	H	CN	6.3	56.6
6c	Bn	H	H	CN	1.6	60.6
7a	Me	Me	Me	CN	> 200	> 128
8	H	Me	Me	CN	> 200	> 128
9	Me	H	Me	CONH ₂	NT ^g	> 128
STS ^c					128	14.7
Cipro ^d					0.1	-

Compound	R ¹	R ²	R ³	R ⁴	MIC ^a (<i>B. anthracis</i>) (μ M)	MIC ^b (<i>M. tuberculosis</i>) (μ M)
RMP ^e					-	0.1
INH ^f					-	0.6

^aMIC = minimum inhibitory concentration against Δ ANR *B. anthracis*

^bMIC against H37Rv *M. tuberculosis*

^cStaurosporine

^dCiprofloxacin hydrochloride

^eRifampin

^fIsoniazid

^gnot tested.